Additionally, in a pancreatic cancer model, endothelial monocyte activating polypeptide II (EMAP II) inhibits fibronectin-integrin angiogenesis signalling, which results in a significant reduction in tumour development and a decrease in microvessel density and proliferative activity [288]. Here, AIMP1 is linked to neoplasm.